FDA approves new pill that nearly doubles pancreatic cancer survival time

The FDA has approved a breakthrough daily pill, Darak Sondra Zib (Razon Q), for patients with metastatic pancreatic cancer. In clinical trials, the drug nearly doubled median survival rates compared to standard chemotherapy. By targeting the mutated KRAS gene, it slows cancer cell growth and offers a more convenient administration method than traditional IV infusions.